著者
Satoshi Kutsuna
出版者
National Center for Global Health and Medicine
雑誌
Global Health & Medicine (ISSN:24349186)
巻号頁・発行日
vol.2, no.2, pp.78-88, 2020-04-30 (Released:2020-05-10)
参考文献数
69

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by SARS-CoV-2. As of March 30, 2020, there have been 693,224 reported patients with COVID-19 worldwide, with 1,446 in Japan. Currently, although aspects of the route of transmission are unclear, infection by contact and by inhaling droplets is considered to be the dominant transmission route. Inflammatory symptoms in the upper respiratory tract persist for several days to 1 week after onset, and in some patients symptoms of pneumonia worsen and become severe. The presence of underlying diseases and advanced age are risk factors for increased severity. Diagnosis is based on detection of SARS-CoV-2 by polymerase chain reaction (PCR) testing of nasopharyngeal swabs or sputum. Symptomatic management is the main treatment for this disease. Although the efficacy of several agents is currently being tested, at present there is no effective therapeutic agent. To prevent infection, in addition to standard preventive measures, measures that counteract infection by contact and droplet inhalation are important. In addition, if procedures that cause aerosolization of virus are used, then measures that prevent airborne infection should be implemented.

言及状況

外部データベース (DOI)

Twitter (2 users, 4 posts, 2 favorites)

感染者の中で無症候性の症例が多いことを特徴とするCOVID-19の分析に基づいた対策がとられている。これらの無症候性の症例のほとんどは感染を広げない→総説を読んでいない! Coronavirus disease 2019 (COVID-19): research progress and clinical practice Satoshi Kutsuna https://t.co/LulcWQZZko
2020年3月末時点でのウイルス学的特徴、伝播様式、臨床症状、検査、治療薬の進展、感染対策などに関する総説。厚生労働省が提示していた「4日間続く発熱」のルールや、日本感染症学会の新型コロナウイルス感染症 治療指針など、特に日本の臨床医の立場から記載 Kutsuna S. https://t.co/EFZ3EuW1pE

収集済み URL リスト